Clinical, Translational, and Basic Science Research
Research holds a place of prominence in the Department of Internal Medicine. In keeping with the overall mission of The Ohio State University Wexner Medical Center to “improve patients’ lives through research,” the department has a committed faculty of clinical, translational and basic scientists working to discover breakthroughs to end human suffering.
Research programs here encompass understanding basic mechanisms of gene and protein dysregulation that result in disease, through translational projects that endeavor to develop new diagnostics and therapeutics for disease intervention, to clinical trials of new medications in patient populations. In all types of scientific inquiry, the research is patient-centered.
Clinical Trials
A phase ii, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMS-986256 in participants with active systemic lupus erythematosus.
A phase iii, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of obinutuzumab in patients with systemic lupus erythematosus.
A phase ib, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered CUG252 following multiple dose administrations in participants with mild-to-moderate systemic lupus erythematosus.
Systemic Lupus Erythematosus Treatment with N-acetylcysteine.
Principal Investigator: Judith Lin
A phase ii/iii, randomized, double-blinded, placebo-controlled, parallel-group, 2-arm, multicenter, operationally seamless study to evaluate the efficacy, safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of efgartigimod PH20 SC in participants aged 18 years and older with active idiopathic inflammatory myopathy.
Principal Investigator: Jisna Paul
A randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis.
Principal Investigator: Ali Ajam